Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors

被引:4
|
作者
Yi, Min [1 ]
Lin, Heather [2 ]
Bedrosian, Isabelle [1 ]
Shen, Yu [2 ]
Hunt, Kelly K. [1 ]
Chavez-MacGregor, Mariana [3 ,4 ]
King, Tari A. [5 ,6 ]
Mittendorf, Elizabeth A. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
关键词
SURVIVAL; VALIDATION; BURDEN;
D O I
10.1245/s10434-019-07983-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The American Joint Committee on Cancer (AJCC) breast cancer pathological prognostic stage, which incorporates biologic factors, was developed using data from patients undergoing upfront surgery, and its application in patients receiving neoadjuvant chemotherapy (NAC) is unknown. We previously developed the Neo-Bioscore, incorporating clinical and pathological TNM categories with biologic factors, to improve the prognostic stratification of NAC patients. Objective. This study was undertaken to evaluate the use of available staging models incorporating biologic factors in NAC patients. Methods. Patients treated with NAC between 2005 and 2012 at MD Anderson (n = 2363) were staged using the Neo-Bioscore and the AJCC 8th edition: (1) clinical anatomic stage; (2) pathological anatomic stage; (3) clinical prognostic stage; and (4) pathological prognostic stage. Five-year disease-specific survival (DSS) and overall survival (OS) rates, along with Harrell's concordance index (C-index), were estimated. A National Cancer Database (NCDB) cohort (n = 12,887) treated with NAC between 2010 and 2013 was used for validation. Results. In the MD Anderson cohort, staging systems incorporating biologic factors better predicted DSS (bias-corrected C-index: pathological prognostic stage = 0.8026; Neo-Bioscore = 0.7483) and OS (bias-corrected C-index: pathological prognostic stage = 0.7780; Neo-Bioscore = 0.7260) than those using anatomic factors only. Similar results were seen in the NCDB cohort. In pairwise comparisons, the pathological prognostic stage was significantly better (p < 0.0001) than other staging systems in all comparisons except for OS in the NCDB cohort, where it was not significantly different than the Neo-Bioscore (p = 0.2). Conclusion. Biologic factors are important for determining prognosis in patients receiving NAC. These data indicate that the 8th edition AJCC pathological prognostic stage is applicable in these patients.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [31] The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy
    Uruena, Claudia
    Lasso, Paola
    Bernal-Estevez, David
    Rubio, Diego
    Salazar, Ana Janeth
    Olaya, Mercedes
    Barreto, Alfonso
    Tawil, Mauricio
    Torregrosa, Lilian
    Fiorentino, Susana
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [32] Neoadjuvant chemotherapy for operable breast cancer
    Mieog, J. S. D.
    van der Hage, J. A.
    de Velde, C. J. H. van
    BRITISH JOURNAL OF SURGERY, 2007, 94 (10) : 1189 - 1200
  • [33] Adjuvant and neoadjuvant chemotherapy of breast cancer
    Untch, M.
    Thomssen, C.
    ONKOLOGE, 2015, 21 (03): : 231 - 238
  • [34] Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
    Marme, Frederik
    Solbach, Christine
    Michel, Laura
    Schneeweiss, Andreas
    Blohmer, Jens-Uwe
    Huober, Jens
    Fasching, Peter A.
    Jackisch, Christian
    Nekljudova, Valentina
    Link, Theresa
    Rhiem, Kerstin
    Rey, Julia
    Denkert, Carsten
    Hanusch, Claus
    Tesch, Hans
    Lederer, Bianca
    Loibl, Sibylle
    Untch, Michael
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 203 - 212
  • [35] Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy
    Wang, Tingting
    Wang, Jinnan
    Zhao, Wei
    Pan, Yueyin
    CLINICAL BREAST CANCER, 2024, 24 (05) : e370 - e378.e1
  • [36] Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
    Shao, Yingbo
    Guan, Huijuan
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Chen, Qi
    Liu, Chaojun
    Zhu, Fangyuan
    Liu, Hui
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [37] The Prognostic and Predictive Significance of PARP-1 in Locally Advanced Breast Cancer of Egyptian Patients Receiving Neoadjuvant Chemotherapy
    Aiad, Hayam A.
    Kandil, Mona A. H.
    El-Tahmody, Mohammed A.
    Abulkheir, Iman L.
    Abulkasem, Fatma M.
    Elmansori, Asma A.
    Aleskandarany, Mohammed A.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2015, 23 (08) : 571 - 579
  • [38] Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
    Dong, Jie
    Sun, Qingqing
    Pan, Yueyin
    Lu, Nannan
    Han, Xinghua
    Zhou, Qiong
    BMC CANCER, 2021, 21 (01)
  • [39] The Effect of Blood Selenium Level on the pCR Rate in Breast Cancer Patient Receiving Neoadjuvant Chemotherapy
    Szwiec, Marek
    Tomiczek-Szwiec, Joanna
    Marciniak, Wojciech
    Derkacz, Roza
    Huzarski, Tomasz
    Cybulski, Cezary
    Gronwald, Jacek
    Osowiecka, Karolina
    Sibilski, Robert
    Narod, Steven A.
    Lubinski, Jan
    CANCERS, 2025, 17 (05)
  • [40] Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Bergquist, John R.
    Murphy, Brittany L.
    Storlie, Curtis B.
    Habermann, Elizabeth B.
    Boughey, Judy C.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (12) : 3510 - 3517